Natera (NASDAQ:NTRA) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.
Other analysts have also issued research reports about the company. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Cowen reiterated a “buy” rating and set a $12.00 target price on shares of Natera in a research note on Thursday, December 21st. Morgan Stanley reiterated an “overweight” rating and set a $16.00 target price (up previously from $13.00) on shares of Natera in a research note on Friday, October 6th. Canaccord Genuity reiterated a “buy” rating and set a $15.00 target price on shares of Natera in a research note on Tuesday, November 14th. Finally, Robert W. Baird reiterated a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $14.50.
Natera (NASDAQ:NTRA) opened at $11.11 on Friday. Natera has a 52-week low of $7.35 and a 52-week high of $14.76. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43. The company has a market capitalization of $597.37, a P/E ratio of -4.53 and a beta of 2.07.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $56.66 million during the quarter, compared to the consensus estimate of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. Natera’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) EPS. equities analysts predict that Natera will post -2.15 EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Capital World Investors boosted its holdings in shares of Natera by 0.8% in the 2nd quarter. Capital World Investors now owns 4,222,609 shares of the medical research company’s stock valued at $45,858,000 after purchasing an additional 32,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Natera by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock valued at $24,555,000 after purchasing an additional 253,344 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in shares of Natera by 23.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,576,190 shares of the medical research company’s stock valued at $20,317,000 after purchasing an additional 300,000 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in shares of Natera by 25.9% in the 3rd quarter. Macquarie Group Ltd. now owns 1,336,993 shares of the medical research company’s stock valued at $17,234,000 after purchasing an additional 275,113 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Natera by 1.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 634,743 shares of the medical research company’s stock valued at $6,893,000 after purchasing an additional 9,223 shares in the last quarter. 66.23% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Natera (NTRA) Stock Rating Upgraded by BidaskClub” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/22/natera-ntra-stock-rating-upgraded-by-bidaskclub.html.
Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.